Build on the technological strengths of Just.

We are developing a drug product portfolio that leverages the strengths of Just’s technology platform against significant health needs. The current product focus can be divided into two broad categories.
Durable Biologics
Just defines Durable Biologics as biosimilar, biobetter or repositioned drugs that will effectively address fundamental disease biology with durable mechanistic efficacy, resisting displacement by other therapeutic approaches. Demand and clinical use could expand indefinitely for Durable Biologics in a growing market where there is a compelling need for high quality, low cost therapeutics
Novel Biologics
Our Novel Biologics will target therapeutic areas where there is an unmet medical need and greater cost sensitivity to treatment. Using antibodies or antibody-like molecules for treatment in areas such as infectious disease, a fast, efficient and low cost approach to development and manufacture could mean the difference between success or failure. This is where Just will add value.
Product Portfolio